Hjem › Blærekreft › Michigan
Kliniske studier for Blærekreft i Michigan
25 studier for Blærekreft søker deltakere på steder i Michigan.
Byer i Michigan
- Grand Rapids12 studier
- Detroit11 studier
- Ann Arbor6 studier
- Farmington Hills6 studier
- Lansing5 studier
- Wyoming4 studier
- Warren4 studier
- Canton4 studier
- Dearborn4 studier
- Livonia4 studier
- Clinton Township4 studier
- Troy3 studier
- Jackson3 studier
- Kalamazoo3 studier
- Waterford3 studier
Offisiell studietekst (engelsk)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06465069Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- og 68 flere
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
Alder 40 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT05334069Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health Medical Center - Brighton, Brighton
- Trinity Health Medical Center - Canton, Canton
- og 8 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06770582A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Profound Research -OMG - TriAtria Cancer Center, Farmington Hills
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06760819Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- og 32 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 30. sep. 2026 · NCT03866382A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
- Munson Medical Center ( Site 0812), Traverse City
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT07419295A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
- Karmanos Cancer Institute, Detroit
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07218380Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- START Midwest, Grand Rapids
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. sep. 2026 · NCT05267626A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- START Midwest, Grand Rapids
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 15. sep. 2026 · NCT07217171ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cancer & Hematology Centers of Western Michigan, Grand Rapids
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05059444Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
- Regents of the University of Michigan, Ann Arbor
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 4. sep. 2026 · NCT07144319Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- Comprehensive Urology, Royal Oak
- Michigan Institute of Urology (Solaris), Troy
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT06567743The Vanguard Study: Testing a New Way to Screen for Cancer
- Henry Ford Cancer Institute-Downriver, Brownstown
- Henry Ford Health Center - Brownstown, Brownstown
- Henry Ford Health Center - Chesterfield, Chesterfield
- og 13 flere
RekruttererFrivillige helsepersonell ønskes velkommen
Alder 45 til 75 · Alle kjønn · Oppdatert 2. sep. 2026 · NCT06995898FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- Barbara Ann Karmanos Cancer Institute, Detroit
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT05614739Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
- Research Site, Grand Rapids
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07129993Measuring Surgical Recovery After Radical Cystectomy
- Spectrum Health Medical Group, Grand Rapids
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT03193970Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
- University of Michigan Rogel Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- University of Michigan - Brighton Center for Specialty Care, Brighton
- og 22 flere
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 18. aug. 2026 · NCT07097142A Study of MGC026 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT06242470A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 11. aug. 2026 · NCT05592626LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- Henry Ford Health System, Detroit
- Corewell Health Medical Group and Spectrum Health Hospitals, Grand Rapids
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 7. aug. 2026 · NCT04752722Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
- Karmanos Cancer Institute, Detroit
RekruttererFase 2/3
Alder 18 og eldre · Alle kjønn · Oppdatert 29. jul. 2026 · NCT07106762A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- The Cancer & Hematology Centers, Big Rapids
- Karmanos Cancer Institute, Detroit
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
- og 7 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jul. 2026 · NCT04879329Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- START Midwest, Grand Rapids
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 18. feb. 2026 · NCT07030257SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Ann Arbor
- Massive Bio SYNERGY-AI site, Lansing
RekruttererObservasjonsstudie
Alle aldre · Alle kjønn · Oppdatert 28. okt. 2025 · NCT03452774A Beta-only IL-2 ImmunoTherapY Study
- Karmanos Cancer Institute, Detroit
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 9. jul. 2025 · NCT05086692Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.